Klaas has over 20 years of venture capital experience spanning Europe, North America and the Middle East.
From 2006 until 2021, he was the Managing Partner of Entrepreneurs Fund, where his managing portfolio included companies such as inge GmbH (sold to BASF), Technolas Perfect Vision (sold to Bausch & Lomb), Prosonix Ltd (sold to Circassia), Lifeline Scientific Inc (sold to Genext), New Motion (sold to Shell) and Optinose (Nasdaq listed). He currently chairs AIM-listed, General Fusion and Xeros Technology Group and serves on the Boards of SmartKem and VeriNOS Pharmaceuticals. Klaas is also an investment committee member for Future Fund: Breakthrough, a UK government-backed direct co-investment fund for late-stage deep tech companies.
LinkedIn